<- Go Home
Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Market Cap
$19.5M
Volume
16.7K
Cash and Equivalents
$26.2M
EBITDA
-$14.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$7.7M
Profit Margin
590.41%
52 Week High
$8.85
52 Week Low
$2.15
Dividend
N/A
Price / Book Value
0.89
Price / Earnings
-1.32
Price / Tangible Book Value
0.89
Enterprise Value
-$5.5M
Enterprise Value / EBITDA
0.37
Operating Income
-$14.8M
Return on Equity
60.22%
Return on Assets
-35.06
Cash and Short Term Investments
$26.2M
Debt
N/A
Equity
$23.3M
Revenue
$1.3M
Unlevered FCF
-$9.3M
Sector
Biotechnology
Category
N/A